ValuentumAd

Official PayPal Seal

Vertex Pharma Is One of Our Favorite Biotechs

publication date: Feb 11, 2025
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Image: Vertex Pharma has performed quite well since the beginning of 2023. 

Looking to 2025, Vertex expects total revenue of $11.75-$12 billion, which includes expectations for continued growth in its cystic fibrosis portfolio, “including the U.S. launch of ALYFTREK, as well as continued uptake of CASGEVY in multiple regions; and early contributions from the launch of JOURNAVX." Cash and total marketable securities as of the end of last year were $11.2 billion, compared to $13.7 billion at the end of 2023 due to the cash consideration paid to acquire Alpine and share buybacks. Vertex had no traditional debt. We continue to like Vertex Pharma as a holding in the Best Ideas Newsletter portfolio.


Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please login.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.